Seek Returns

ILMN vs. RVMD: Illumina vs. Revolution Medicines Stock Comparison

How do Illumina (ILMN) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Illumina (ILMN) has more than two decades of public-market history since July 28, 2000, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Company profile comparison for Illumina (ILMN) and Revolution Medicines (RVMD)
Profile ItemILMNRVMD
NameIllumina Inc.Revolution Medicines, Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization32.23 billion USD41.59 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 28, 2000February 13, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ILMN
RVMD
GSPC
Loading price history…
Illumina (ILMN) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Illumina (ILMN) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Illumina (ILMN) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
Total Return (1Y)79.70%224.80%
Total Return (3Y, Annualized)28.16%114.71%
Total Return (5Y, Annualized)-10.65%43.47%

Risk Profile

Drawdown History

ILMN
RVMD
GSPC
Loading price history…
Illumina (ILMN) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Illumina (ILMN) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
Volatility (1Y, Annualized)48.47%68.29%
Beta (5Y)1.461.42
Max Drawdown (5Y)-82.95%-55.71%
Avg. Volume (3M)2.77M2.06M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ILMN and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
Sharpe Ratio (1Y)1.563.23
Sortino Ratio (1Y)2.256.92

Profitability

ROE (TTM)

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
RVMD
-93.56%
Min
-167.77%
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Illumina (ILMN) at 19.72% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
RVMD
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Illumina (ILMN) reports 20.02%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
RVMD
-188.88%
Min
-207.40%
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
ROE (TTM)32.39%-93.56%
ROA (TTM)8.32%-32.13%
Net Margin (TTM)19.72%0.00%
Operating Margin (TTM)20.02%-188.88%
Gross Margin (TTM)67.68%0.00%

Growth

Revenue Growth

Only one side can be read here: Illumina (ILMN) reports revenue growth of -0.66%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Illumina (ILMN) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
Revenue Growth (YoY)-0.66%--
Revenue Growth (3Y CAGR)-1.78%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Illumina (ILMN) at 2.63 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max
25.13
Q3
12.13
RVMD
8.36
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revolution Medicines (RVMD) at 0.50 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max
1.42
Q3
0.65
RVMD
0.50
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
Current Ratio (MRQ)2.638.36
Debt / Equity (MRQ)0.740.50
Net Debt / EBITDA0.85--

Dividends

Dividend Yield (TTM)

Neither Illumina (ILMN) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Illumina (ILMN) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RVMD
--
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): RVMD does not report P/E ratio, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Illumina (ILMN) at 7.10 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD
210.51
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD
17.31
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Illumina (ILMN) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Revolution Medicines (RVMD)
MetricILMNRVMD
P/E Ratio (TTM)36.68--
P/S Ratio (TTM)7.10210.51
P/B Ratio (MRQ)10.3017.31
Free Cash Flow Yield (TTM)2.67%-2.13%